Dr. Buchanan will helm Belharra's research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches its ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Additionally, rapid, substantial and sustained statistically significant reductions in 17-OHP, a confirmatory secondary biomarker of disease control, were achieved across doses. Treatment with ...

Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases ...

A comprehensive retrospective celebrating the extraordinary career of Wim Wenders, this landmark event marks the 79-year-old ...